2016
DOI: 10.4172/2165-7920.1000811
|View full text |Cite
|
Sign up to set email alerts
|

Small Cell Carcinoma of the Upper Urinary Tract: A Case Report and Review of Existing Cases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2017
2017
2018
2018

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 6 publications
0
2
0
Order By: Relevance
“…Ouzzane et al [ 4 ] reviewed 39 cases and noted that a platinum and etoposide adjuvant regimen increased survival as compared to surgery alone in patients with EPSCC of the upper urinary tract, but this difference was not statistically significant. However, many case reports and single-institution experiences have shown a significant increase in median survival with chemotherapy [ 3 , 4 , 7 , 8 , 9 , 10 , 11 ]. Dakhil et al [ 3 ] reviewed 35 cases from the University of Kansas tumor registry and found that a platinum-based agent with etoposide improved median survival to 36 months compared to 5 months without chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Ouzzane et al [ 4 ] reviewed 39 cases and noted that a platinum and etoposide adjuvant regimen increased survival as compared to surgery alone in patients with EPSCC of the upper urinary tract, but this difference was not statistically significant. However, many case reports and single-institution experiences have shown a significant increase in median survival with chemotherapy [ 3 , 4 , 7 , 8 , 9 , 10 , 11 ]. Dakhil et al [ 3 ] reviewed 35 cases from the University of Kansas tumor registry and found that a platinum-based agent with etoposide improved median survival to 36 months compared to 5 months without chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…EPSCC of the upper urinary tract, in particular, has had no more than 40 cases reported in the literature [ 4 , 5 ]. The current knowledge of these rare tumors is limited, and treatment recommendations are mainly based on case reports, single-institution case series, or the extrapolation of results from pulmonary SCC [ 1 , 3 , 4 , 5 , 6 , 7 , 8 ]. No consensus guideline exists, and further work is necessary to better our understanding of how to best manage these patients.…”
Section: Introductionmentioning
confidence: 99%